Literature DB >> 15385530

The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia.

Patrick H Corran1, Rebecca A O'Donnell, Jim Todd, Chairat Uthaipibull, Anthony A Holder, Brendan S Crabb, Eleanor M Riley.   

Abstract

In a cross-sectional survey of 187 Gambian children and adults, we have analyzed prevalence, fine specificity, and 19-kilodalton merozoite surface protein 1 (MSP-1(19))-specific erythrocyte invasion inhibitory activity of antibodies to MSP-1(19) but find no significant association between any of these parameters and prevalence or density of malarial parasitemia, except that, after correcting for total anti-MSP-1(19) antibody levels, individuals with anti-MSP-1(19) antibodies that compete with an invasion inhibitory monoclonal antibody (12.10) were significantly less likely to have malaria infections with densities of > or =1,000 parasites/microl than were individuals without such antibodies. This association persisted after correction for age and ethnic origin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385530      PMCID: PMC517553          DOI: 10.1128/IAI.72.10.6185-6189.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon region.

Authors:  Erika Martins Braga; Rosa Maria Barros; Tânia Afonso Reis; Cor Jesus F Fontes; Cristiane Guimarães Morais; Maria Sĵnia Martins; Antoniana Ursine Krettli
Journal:  Am J Trop Med Hyg       Date:  2002-05       Impact factor: 2.345

2.  A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.

Authors:  Anthony W Stowers; Li-how Chen Lh; Yanling Zhang; Michael C Kennedy; Lanling Zou; Lynn Lambert; Timothy J Rice; David C Kaslow; Allan Saul; Carole A Long; Harry Meade; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species.

Authors:  R A O'Donnell; A Saul; A F Cowman; B S Crabb
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

4.  Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.

Authors:  S Kumar; W Collins; A Egan; A Yadava; O Garraud; M J Blackman; J A Guevara Patino; C Diggs; D C Kaslow
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

5.  Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.

Authors:  A W Stowers; V Cioce; R L Shimp; M Lawson; G Hui; O Muratova; D C Kaslow; R Robinson; C A Long; L H Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

6.  Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine.

Authors:  Evelina Angov; Barbara M Aufiero; Ann Marie Turgeon; Michel Van Handenhove; Christian F Ockenhouse; Kent E Kester; Douglas S Walsh; Jana S McBride; Marie-Claude Dubois; Joe Cohen; J David Haynes; Kenneth H Eckels; D Gray Heppner; W Ripley Ballou; Carter L Diggs; Jeffrey A Lyon
Journal:  Mol Biochem Parasitol       Date:  2003-05       Impact factor: 1.759

Review 7.  Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria.

Authors:  A A Holder; J A Guevara Patiño; C Uthaipibull; S E Syed; I T Ling; T Scott-Finnigan; M J Blackman
Journal:  Parassitologia       Date:  1999-09

8.  Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum.

Authors:  C Uthaipibull; B Aufiero; S E Syed; B Hansen; J A Guevara Patiño; E Angov; I T Ling; K Fegeding; W D Morgan; C Ockenhouse; B Birdsall; J Feeney; J A Lyon; A A Holder
Journal:  J Mol Biol       Date:  2001-04-13       Impact factor: 5.469

9.  Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.

Authors:  R A O'Donnell; T F de Koning-Ward; R A Burt; M Bockarie; J C Reeder; A F Cowman; B S Crabb
Journal:  J Exp Med       Date:  2001-06-18       Impact factor: 14.307

10.  The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies.

Authors:  Roseangela I Nwuba; Olugbemiro Sodeinde; Chiaka I Anumudu; Yusuf O Omosun; Alexander B Odaibo; Anthony A Holder; Mark Nwagwu
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more
  37 in total

1.  Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized.

Authors:  Kazutoyo Miura; Hong Zhou; Ababacar Diouf; Gregory Tullo; Samuel E Moretz; Joan A Aebig; Michael P Fay; Louis H Miller; Ogobara K Doumbo; Issaka Sagara; Alassane Dicko; Carole A Long; Ruth D Ellis
Journal:  Vaccine       Date:  2011-01-31       Impact factor: 3.641

2.  Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development.

Authors:  David K Moss; Edmond J Remarque; Bart W Faber; David R Cavanagh; David E Arnot; Alan W Thomas; Anthony A Holder
Journal:  Infect Immun       Date:  2011-12-27       Impact factor: 3.441

3.  Levels of plasma immunoglobulin G with specificity against the cysteine-rich interdomain regions of a semiconserved Plasmodium falciparum erythrocyte membrane protein 1, VAR4, predict protection against malarial anemia and febrile episodes.

Authors:  John P A Lusingu; Anja T R Jensen; Lasse S Vestergaard; Daniel T Minja; Michael B Dalgaard; Samwel Gesase; Bruno P Mmbando; Andrew Y Kitua; Martha M Lemnge; David Cavanagh; Lars Hviid; Thor G Theander
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

5.  Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.

Authors:  Matthew B McCarra; George Ayodo; Peter O Sumba; James W Kazura; Ann M Moormann; David L Narum; Chandy C John
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

6.  Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam.

Authors:  E Elsa Herdiana Murhandarwati; Lina Wang; Casilda G Black; Doan Hanh Nhan; Thomas L Richie; Ross L Coppel
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

7.  Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.

Authors:  Suman Mazumdar; Paushali Mukherjee; Syed Shams Yazdani; S K Jain; Asif Mohmmed; Virander Singh Chauhan
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

Review 8.  Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design.

Authors:  Rosalynn L Ord; Marilis Rodriguez; Cheryl A Lobo
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 9.  What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity.

Authors:  Samson M Kinyanjui; Philip Bejon; Faith H Osier; Peter C Bull; Kevin Marsh
Journal:  Malar J       Date:  2009-10-28       Impact factor: 2.979

10.  Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in The Gambia and Guinea Bissau.

Authors:  Judith Satoguina; Brigitte Walther; Christopher Drakeley; Davis Nwakanma; Eniyou C Oriero; Simon Correa; Patrick Corran; David J Conway; Michael Walther
Journal:  Malar J       Date:  2009-12-02       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.